APA (7th ed.) Citation

J, K., M, M., M, P., S, H., C, H., C, T., . . . JS, H. (2022). BCR: :ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro. Journal of cancer research and clinical oncology, 148(10), 2759. https://doi.org/10.1007/s00432-022-04039-5

Chicago Style (17th ed.) Citation

J, Kauer, Märklin M, Pflügler M, Hörner S, Hinterleitner C, Tandler C, Jung G, Salih HR, and Heitmann JS. "BCR: :ABL1 Tyrosine Kinase Inhibitors Hamper the Therapeutic Efficacy of Blinatumomab in Vitro." Journal of Cancer Research and Clinical Oncology 148, no. 10 (2022): 2759. https://doi.org/10.1007/s00432-022-04039-5.

MLA (9th ed.) Citation

J, Kauer, et al. "BCR: :ABL1 Tyrosine Kinase Inhibitors Hamper the Therapeutic Efficacy of Blinatumomab in Vitro." Journal of Cancer Research and Clinical Oncology, vol. 148, no. 10, 2022, p. 2759, https://doi.org/10.1007/s00432-022-04039-5.